Milbury Max A. 4

What Happened
Max A. Milbury, Principal Accounting Officer of ProMIS Neurosciences (PMN), acquired 6,595 common shares on February 3, 2026 at $12.13 per share for a total cash outlay of $79,997. He also received Common Share Warrants exercisable for 6,595 shares (recorded as a derivative acquisition). The purchases were made under a Securities Purchase Agreement with selected investors.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely within required reporting window).
• Share purchase: 6,595 common shares at $12.13 each = $79,997.
• Derivative: Common Share Warrants to purchase 6,595 shares (warrant entry reported as N/A for price/value on the Form 4).
• Post-transaction beneficial ownership: not specified on this filing.
• Notable footnotes: (F1) Shares and warrants acquired under a Securities Purchase Agreement; (F2) figures reflect a 1-for-25 reverse split effective Nov 28, 2025; (F3) warrants expire on the earlier of Feb 3, 2031 or within 60 days after a public announcement of topline single-ascending-dose PMN310 cohort data.

Context
This was a direct purchase in a private placement (not an open-market sale). The addition of warrants means Milbury can buy the same number of shares later under specified terms and expiration triggers tied to clinical data timing. Purchases by insiders are often watched by investors as a stronger signal than routine sales, but this summary is factual and does not infer motive.